+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

D

Actively Recruiting

Researchers are evaluating KTX-2001, alone and combined with darolutamide, in men with metastatic castration-resistant prostate cancer mCRPC. This Phase 1, open-label study aims to assess the safety, dosage limits, how the drugs behave in the body, and preliminary effectiveness in treating mCRPC. The trial also seeks to establish recommended doses for future studies. Participants receive escalating doses of KTX-2001 by mouth either alone or together with oral darolutamide at a total daily dose of 1200 mg. The study has two parts Part A focuses on KTX-2001 alone, and Part B studies the combination with darolutamide. Dose escalation continues to determine safe and tolerable levels. During the study, participants undergo baseline and on-treatment biopsies when feasible, imaging scans to confirm metastatic disease, and regular safety monitoring. Researchers measure dose-limiting toxicities within 21 days to find the maximum tolerated dose, along with pharmacokinetics, safety events over up to 3 years, and recommended dosing. Participants are closely observed throughout treatment and follow-up periods until study completion.

Age: 18Years +MALEPhase 1
13 locations
S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of HCB101, an intravenous Fc-fusion protein targeting the SIRP-CD47 pathway, in adults aged 18 years and older with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. This Phase 1, open-label, multi-center study aims to identify the maximum tolerated dose and monitor any side effects in participants who have failed standard therapies or are considered unsuitable for such treatments. Participants will receive HCB101 through intravenous injection at gradually increasing doses, starting from 0.08 mgkg up to 36 mgkg sequentially. Treatment will continue until unacceptable adverse events, disease progression, withdrawal, loss to follow-up, death, or study termination. The study involves dose escalation to determine the optimal dose level for further research. During the study, participants will undergo regular safety monitoring, blood sampling for pharmacokinetics, and tumor assessments using established criteria. Researchers will measure adverse event rates, immune responses, tumor response rates, and drug concentration over a 12-month period. The study includes comprehensive evaluation of anti-tumor effects and safety, with participants followed until study completion or withdrawal.

Age: 18Years +All GendersPhase 1
8 locations
S

Actively Recruiting

This research aims to describe the characteristics of people with asthma, covering a wide range of disease severities. It studies sociodemographic and clinical features, treatment patterns, disease burden, biomarkers, and health-related quality of life. The study includes both a cross-sectional part and a prospective follow-up to observe changes in asthma over time. Participants are grouped based on their asthma treatments and disease control, including those receiving various doses of inhaled corticosteroids or biologic therapies as part of their usual care. The study has two main parts Part 1 assesses characteristics at baseline, while Part 2 follows participants for two years to evaluate changes in symptoms, lung function, treatment use, and biomarkers. During the study, participants will provide information through questionnaires and clinical assessments, including lung tests and blood samples. Researchers will collect both participant- and physician-reported outcomes to analyze asthma severity, control, quality of life, and healthcare use. The study extends up to two years, with evaluations at baseline and at weeks 52 and 104 to understand disease progression and treatment patterns.

Age: 6Years +All Genders
71 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
P

Actively Recruiting

Researchers are evaluating DB-1324 in people with advanced or metastatic gastrointestinal tumors in a first-in-human Phase 12 clinical trial. The study aims to understand the safety, tolerability, how the drug moves and acts in the body, the maximum dose that can be tolerated, and the potential antitumor activity of DB-1324. This trial is open-label and multicenter, focusing on participants who have malignant GI tumors that have progressed after standard treatments or have no standard options. Participants will receive DB-1324 intravenously in multiple dosing schedules across different study parts. Phase 1 includes dose escalation, backfill, and dose expansion to find the maximum tolerated dose and recommended doses for later phases. Phase 2 will further explore safety and possible efficacy in selected GI tumor groups. Treatment continues until disease progression, unacceptable side effects, loss of benefit, participant withdrawal, or other stopping criteria. During the study, participants will have evaluations for adverse events, dose-limiting toxicities, and pharmacokinetic measures up to about 30 days after treatment. Researchers will also assess tumor response and survival outcomes over approximately three years. Participants will undergo tumor biopsies or provide archived tissue to measure biomarkers. Safety monitoring, including heart function and organ tests, will be part of the assessments throughout the study.

Age: 18Years +All GendersPhase 1Phase 2
9 locations
E

Actively Recruiting

Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
89 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
P

Actively Recruiting

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.

Age: 18Years +All GendersPhase 3
265 locations

1-10 of 27

1